Detrusor overactivity is associated with downregulation of large-conductance calcium- and voltage-activated potassium channel protein.
Large-conductance voltage- and calcium-activated potassium (BK) channels have been shown to play a role in detrusor overactivity (DO). The goal of this study was to determine whether bladder outlet obstruction-induced DO is associated with downregulation of BK channels and whether BK channels affect myosin light chain 20 (MLC(20)) phosphorylation in detrusor smooth muscle (DSM). Partial bladder outlet obstruction (PBOO) was surgically induced in male New Zealand White rabbits. The rabbit PBOO model shows decreased voided volumes and increased voiding frequency. DSM from PBOO rabbits also show enhanced spontaneous contractions compared with control. Both BK channel alpha- and beta-subunits were significantly decreased in DSM from PBOO rabbits. Immunostaining shows BKbeta mainly expressed in DSM, and its expression is much less in PBOO DSM compared with control DSM. Furthermore, a translational study was performed to see whether the finding discovered in the animal model can be translated to human patients. The urodynamic study demonstrates several overactive DSM contractions during the urine-filling stage in benign prostatic hyperplasia (BPH) patients with DO, while DSM is very quiet in BPH patients without DO. DSM biopsies revealed significantly less BK channel expression at both mRNA and protein levels. The degree of downregulation of the BK beta-subunit was greater than that of the BK alpha-subunit, and the downregulation of BK was only associated with DO, not BPH. Finally, the small interference (si) RNA-mediated downregulation of the BK beta-subunit was employed to study the effect of BK depletion on MLC(20) phosphorylation. siRNA-mediated BK channel reduction was associated with an increased MLC(20) phosphorylation level in cultured DSM cells. In summary, PBOO-induced DO is associated with downregulation of BK channel expression in the rabbit model, and this finding can be translated to human BPH patients with DO. Furthermore, downregulation of the BK channel may contribute to DO by increasing the basal level of MLC(20) phosphorylation.
Chang
Shaohua
S
Division of Urology, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gomes
Cristiano Mendes
CM
Hypolite
Joseph A
JA
Marx
James
J
Alanzi
Jaber
J
Zderic
Stephen A
SA
Malkowicz
Bruce
B
Wein
Alan J
AJ
Chacko
Samuel
S
D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D016022:Case-Control Studies; D002478:Cells, Cultured; D004195:Disease Models, Animal; D015536:Down-Regulation; D006801:Humans; D051037:Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / Q000819:agonists / Q000378:metabolism*; D051038:Large-Conductance Calcium-Activated Potassium Channel beta Subunits / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D032389:Myocytes, Smooth Muscle / Q000378:metabolism / Q000473:pathology; D018994:Myosin Light Chains / Q000378:metabolism; D010766:Phosphorylation; D011188:Potassium / Q000378:metabolism*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D034622:RNA Interference; D012333:RNA, Messenger / Q000378:metabolism; D011817:Rabbits; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D001748:Urinary Bladder Neck Obstruction / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology; D053201:Urinary Bladder, Overactive / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D014563:Urodynamics
D001562:Benzimidazoles; D051037:Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; D051038:Large-Conductance Calcium-Activated Potassium Channel beta Subunits; D018994:Myosin Light Chains; D012333:RNA, Messenger; C086491:NS 1619; D011188:Potassium
Gen Pharmacol. 1998 Aug;31(2):291-5
9688475
Am J Physiol Renal Physiol. 2004 Oct;287(4):F682-9
15161603
Neurourol Urodyn. 1997;16(1):1-18
9021786
J Urol. 1986 Aug;136(2):517-21
2874238
Urology. 2003 Nov;62(5 Suppl 2):3-10
14662401
Am J Physiol. 1997 Jul;273(1 Pt 1):C110-7
9252448
J Urol. 2000 Sep;164(3 Pt 2):1026-30
10958733
BJU Int. 1999 Jul;84(1):14-5
10444116
Neurourol Urodyn. 2002;21(2):167-78
11857671
Am J Physiol Renal Physiol. 2003 Apr;284(4):F644-52
12505863
Am J Pathol. 2004 Feb;164(2):601-12
14742265
Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L802-10
16632519
Science. 1981 Jan 30;211(4481):495-7
6893872
Prostate Suppl. 1990;3:9-26
1689174
J Urol. 2000 Aug;164(2):344-8
10893581
Am J Physiol Cell Physiol. 2003 Dec;285(6):C1397-410
12890650
BJU Int. 2008 Jun;101(12):1588-94
18294303
Physiol Rev. 2003 Oct;83(4):1325-58
14506307
J Physiol. 2001 Dec 1;537(Pt 2):443-52
11731577
Am J Physiol Renal Physiol. 2003 Nov;285(5):F990-7
12851253
J Biol Chem. 1994 Jan 7;269(1):676-82
7506261
Scand J Urol Nephrol Suppl. 2004;(215):26-36
15545194
Neurourol Urodyn. 1998;17(2):99-108
9514142
Am J Physiol Renal Physiol. 2005 Sep;289(3):F604-10
15827347
Am J Physiol Regul Integr Comp Physiol. 2000 Jul;279(1):R60-8
10896865
J Biol Chem. 2004 Aug 27;279(35):36746-52
15184377
Nature. 1994 Nov 17;372(6503):231-6
7969467
Am J Physiol Cell Physiol. 2001 Feb;280(2):C254-64
11208519